| pubmed-article:20414207 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20414207 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:20414207 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:20414207 | lifeskim:mentions | umls-concept:C0805586 | lld:lifeskim |
| pubmed-article:20414207 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:20414207 | lifeskim:mentions | umls-concept:C0079411 | lld:lifeskim |
| pubmed-article:20414207 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:20414207 | pubmed:dateCreated | 2010-4-23 | lld:pubmed |
| pubmed-article:20414207 | pubmed:abstractText | Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions. | lld:pubmed |
| pubmed-article:20414207 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20414207 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20414207 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20414207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20414207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20414207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20414207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20414207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20414207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20414207 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20414207 | pubmed:month | May | lld:pubmed |
| pubmed-article:20414207 | pubmed:issn | 1474-1741 | lld:pubmed |
| pubmed-article:20414207 | pubmed:author | pubmed-author:BaillyChristi... | lld:pubmed |
| pubmed-article:20414207 | pubmed:author | pubmed-author:WurchThierryT | lld:pubmed |
| pubmed-article:20414207 | pubmed:author | pubmed-author:BeckAlainA | lld:pubmed |
| pubmed-article:20414207 | pubmed:author | pubmed-author:CorvaiaNathal... | lld:pubmed |
| pubmed-article:20414207 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20414207 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:20414207 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20414207 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20414207 | pubmed:pagination | 345-52 | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:meshHeading | pubmed-meshheading:20414207... | lld:pubmed |
| pubmed-article:20414207 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20414207 | pubmed:articleTitle | Strategies and challenges for the next generation of therapeutic antibodies. | lld:pubmed |
| pubmed-article:20414207 | pubmed:affiliation | Centre d'Immunologie Pierre Fabre (CIPF), 5 Avenue Napoléon III, F74160, Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com | lld:pubmed |
| pubmed-article:20414207 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20414207 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20414207 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20414207 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20414207 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20414207 | lld:pubmed |
